Concord Biotech has appointed Raviraj Karia as its Chief Financial Officer (CFO), effective December 18, 2025. The decision was approved during a board meeting. Karia brings over 23 years of experience in pharmaceuticals, healthcare, and finance leadership roles. This appointment aims to strengthen the company’s financial discipline and governance frameworks.
CFO Appointment
Raviraj Karia has been appointed as the Chief Financial Officer (CFO) of Concord Biotech, effective December 18, 2025. This appointment follows the recommendation of the Nomination and Remuneration Committee and the Audit Committee, and approval by the Board of Directors.
About Raviraj Karia
Raviraj Karia is a Chartered Accountant and a senior finance leader with more than 23 years of experience across pharmaceuticals, healthcare, clinical research, logistics, and private equity. His expertise includes corporate governance, strategic finance, and business partnering. He has worked with Boards, Promoters, CEOs, and global leadership teams.
Previous Roles and Expertise
Karia has held leadership roles at Intas Pharmaceuticals, Sakar Healthcare, Lambda Therapeutics, Shalby Hospitals, Gati, GVFL, and Claris Lifesciences. His experience includes managing multi-billion-dollar financing programs, leading India’s largest outbound pharma acquisition, facilitating private equity investments, and executing global audits. He has also driven major cost efficiency programs and implemented digital tools. The company has stated that Karia is not related to any of the Directors of the Company.
Source: BSE
